Monthly information on share capital and company voting rights
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cellectis announces voting rights for March 2024 with a total of 77,889,229 voting rights from 71,953,535 shares in the capital, listed on Euronext Growth with ISIN code FR0010425595.
Positive
- None.
Negative
- None.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, April 04, 2024 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 03/31/2024 | 71,953,535 | 77,889,229 |
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
Cellectis had a total of 77,889,229 voting rights in March 2024.
There are 71,953,535 shares in the capital of Cellectis as of March 31, 2024.
Cellectis is listed on Euronext Growth.
The ISIN code for Cellectis is FR0010425595.
Cellectis S.A. American Depositary Shares
NASDAQ:CLLS
CLLS Rankings
CLLS Latest News
CLLS Stock Data
184.20M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
Paris
About CLLS
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.